替格瑞洛治疗稳定型心绞痛的临床效果分析

目的 探讨替格瑞洛对稳定型心绞痛(SCAD)的治疗效果。方法 回顾性分析2015年8月-2016年8月在我院接受治疗的稳定型心绞痛患者的临床资料。根据其治疗方式分为氯吡格雷治疗组和替格瑞洛治疗组。观察两组的治疗效果,比较两组治疗前后细胞因子、心功能的差异。结果 替格瑞洛治疗组患者治疗的总有效率明显高于氯吡格雷治疗组,差别具有统计学意义(χ2=4.837,P=0.028)；治疗前两组血清细胞因子水平无差别,治疗后,替格瑞洛治疗组的血清CRP、sICAM-1、sVCAM-1低于氯吡格雷治疗组(t=4.455、15.721、45.650,P<0.05)；治疗前两组患者的心功能指标无差别,治疗后,替格瑞洛治疗组的SV、LVPS和LVEF均高于氯吡格雷治疗组(t=-4.307、-3.230、-3.895,P<0.05),NT-proBNP和CTnl均低于氯吡格雷治疗组(t=43.704、9.799,P<0.05)；两组患者半年内再发心绞痛、心肌梗死和心率衰竭发生率无明显差别(Χ2=0.008,P=0.930)。结论 替格瑞洛对稳定型心绞痛有较好的治疗效果,可明显改善患者的心功能,具有临床推广应用价值。

Analysis of clinical effect of the treatment of stable angina pectoris

Objective To investigate the ticagrelor on stable angina pectoris (SCAD) treatment. Methods The clinical data of patients with stable angina who received treatment in our hospital from August 2015 to August 2016 were retrospectively analyzed. According to the treatment, the treatment group was divided into clopidogrel treatment group and treatment group. The treatment effect of the two groups was observed, and the differences of cytokines and cardiac function before and after treatment were compared between the two groups. Results Ticagrelor patients in the treatment group the total effective rate of treatment was significantly higher than that of clopidogrel in the treatment group, the difference was statistically significant (2=4.837, P=0.028). There was no difference in serum cytokine levels between the two groups before treatment. After treatment, the serum CRP, sICAM-1, and sVCAM-1 in the treated group were lower than that in the clopidogrel group (t=4.455, 15.721, 45.650, P<0.05); The cardiac function indexes of patients in two groups were no difference before treatment, after treatment for Grillo treatment group of SV, LVPS and LVEF were higher than those in the clopidogrel group (t=-4.307, -3.230, -3.895, P<0.05), NT-proBNP and CTnl were lower than those in the clopidogrel group (t=43.704, 9.799, P<0.05). Two groups of patients within six months of recurrent angina, myocardial infarction and heart failure incidence rate showed no significant difference (x 2=0.008, P=0.930). Conclusion Ticagrelor for stable angina has good curative effect, can significantly improve the cardiac function of patients, which has clinical application value.